Table 10.
Late adverse events recorded after concurrent high-dose intensity-modulated radiation therapy and docetaxel-based chemotherapy: genitourinary symptoms
| Grade |
Frequency/urgency |
Dysuria |
Incontinence |
Retention |
Hematuria |
Highest during follow-up |
Highest at last follow-up |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L | L* | L | L* | L | L* | L | L* | L | L* | L | L* | L | L* | ||
| Cohort 1 |
1 |
3 |
1 |
1 |
0 |
2 |
1 |
0 |
0 |
1 |
1 |
5 |
3 |
2 |
1 |
| 2 |
0 |
1 |
0 |
0 |
2 |
1 |
0 |
0 |
1 |
1 |
2 |
1 |
2 |
1 |
|
| 3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
| Cohort 2 |
1 |
3 |
1 |
1 |
0 |
1 |
1 |
2 |
1 |
1 |
1 |
6 |
3 |
4 |
2 |
| 2 |
2 |
1 |
0 |
0 |
1 |
1 |
2 |
1 |
1 |
1 |
3 |
2 |
2 |
1 |
|
| 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
L = all late adverse events; L* = adverse events of higher grade than baseline.